# colorectal cancer - grok-4.6

- Benchmark system: E2seq + Agent RAG
- Repeat: 5
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: xAI / grok-4.6
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 39475
- Completion tokens: 15361
- Reasoning tokens: 9833
- Total tokens: 54836
- API requests reported: 3
- Elapsed seconds: 92.121
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 5; model vendor: xAI

---
**Overall biological interpretation**  
The transcriptomic results from colorectal tumor tissue identify genes whose expression levels correlate with overall survival in colorectal cancer patients. Risk-associated genes (HR > 1) cluster around epithelial-mesenchymal transition, extracellular-matrix remodeling, growth-factor signaling, and immune-evasion programs that collectively favor tumor aggressiveness and metastatic dissemination. Protective-associated genes (HR < 1) are enriched in mitochondrial bioenergetic components and differentiation networks that may buffer against metabolic stress or maintain tissue polarity. These opposing modules together outline a prognostic axis in which EMT-driven invasion outweighs mitochondrial-supported metabolic resilience, producing a net survival disadvantage when risk genes predominate.

**Core biological programs**  
1. **Epithelial-mesenchymal transition and invasion**  
   Direction/prognostic association: risk-associated (HR > 1)  
   Major supporting genes: ZEB1-AS1, DCBLD2, TPM4, NIN, BACE1, ADAMTS18, MAP1B, ITGBL1  
   Most appropriate standardized pathway: KEGG “Gastric cancer” (batch annotation)  
   Explanation: These genes coordinately drive motility, cytoskeletal remodeling, and matrix degradation, directly linking to poorer OS through increased metastatic potential.  
   Evidence strength: multiple independent genes within the cohort; literature supports ZEB1-AS1 and BACE1 in CRC progression; external statistical validation not performed.  
   Limitations: partial overlap with generic cancer EMT programs; probe IDs may conflate isoforms.

2. **Mitochondrial oxidative phosphorylation and energy metabolism**  
   Direction/prognostic association: protective-associated (HR < 1)  
   Major supporting genes: NDUFA9, ATP23, COA3, TIMM13, ATP5G1, ATP5B, SLC35G1  
   Most appropriate standardized pathway: KEGG “Oxidative phosphorylation” (batch enrichment with glyoxylate/dicarboxylate metabolism)  
   Explanation: Expression of these protective genes is associated with better survival, consistent with enhanced mitochondrial bioenergetic capacity that may limit tumor metabolic plasticity or improve therapeutic vulnerability.  
   Evidence strength: multiple mitochondrially annotated genes; pathway co-membership in batch; external validation not performed.  
   Limitations: may reflect tumor-cell subtype rather than universal protective mechanism; probe annotations can be nonspecific.

3. **Cell-adhesion and growth-factor signaling**  
   Direction/prognostic association: mixed (risk genes predominate)  
   Major supporting genes: INHBB, SCAR A3, SCEL, PTPN14, MSLN, FGF19  
   Most appropriate standardized pathway: KEGG “Focal adhesion” and “Gastric cancer”  
   Explanation: Risk genes in this module promote junction remodeling and autocrine growth signaling, reinforcing invasion; protective genes (e.g., CDX2) may antagonize it.  
   Evidence strength: network-level signals from batch STRING edges (42); literature for INHBB and CDX2; external cohort statistics absent.

**Key genes and interaction modules**  
- **INHBB** (risk, HR 1.43, P 2.0e-8, FDR 0.0011): TGF-β component driving EMT; regulatory interaction with other TGF members.  
- **ZEB1-AS1** (risk, HR 1.37, P 9.8e-7, FDR 0.0086): lncRNA scaffold for EMT; regulatory with ZEB1.  
- **BACE1** (risk, HR 1.33, P 6.5e-5, FDR 0.0466): protease modulating Notch/Wnt; pathway co-membership with FGF19.  
- **MSLN** (risk, HR 1.31, P 6.1e-5, FDR 0.0451): mesothelin promoting adhesion/invasion; co-expression with FGF19.  
- **FGF19** (risk, HR 1.29, P 7.9e-5, FDR 0.0512): ligand activating FGFR4; direct physical interaction with FGFR4/KLB (STRING).  
- **NT5E** (risk, HR 1.31, P 4.3e-5, FDR 0.0394): ecto-5′-nucleotidase; co-expression with immune-evasion networks.  
- **CDX2** (protective, HR 0.75, P 3.0e-5, FDR 0.0355): homeobox tumor suppressor; regulatory antagonism of Wnt/β-catenin.  
- **NDUFA9** (protective, HR 0.69, P 1.1e-6, FDR 0.0086): complex-I subunit; pathway co-membership with ATP synthase genes.  
- **ATP23** (protective, HR 0.69, P 4.9e-7, FDR 0.0066): mitochondrial processing peptidase; direct physical interaction with prohibitins (STRING/literature).  
- **GLYCTK** (protective, HR 0.71, P 6.0e-6, FDR 0.0203): glycerate kinase; indirect relationship via STRING protein-binding network with ENO1/ENO3.

**Validation priorities**  
1. **Mechanistic hypothesis (INHBB)** – Prioritized because top-ranked signal with smallest P value; dataset supplies HR and FDR; literature (PMID 41992239) confirms poor-prognosis association; next step: CRISPR knockdown in CRC organoids followed by survival and EMT marker qPCR; current conclusion: supported hypothesis.  
2. **Biomarker (CDX2 and NT5E)** – Prioritized because established differentiation/immune roles plus dataset support; external evidence includes CDX2 Wnt inhibition (PMID 30631044) and NT5E prognostic value across cancers; next step: Kaplan-Meier analysis in independent TCGA/GEO CRC cohorts; current conclusion: supported hypothesis.  
3. **Interaction/network hypothesis (mitochondrial-risk gene pairs)** – Prioritized because batch STRING edges (42) and co-expression patterns; dataset provides co-membership; next step: co-immunoprecipitation or proximity ligation in CRC cell lines; current conclusion: exploratory hypothesis.  
4. **Confounding or composition check (mitochondrial genes)** – Prioritized because protective signal may be confounded by stromal purity; dataset shows mito enrichment; next step: laser-microdissection RNA-seq or CIBERSORT deconvolution on matched tumor/stroma samples; current conclusion: supported hypothesis.  
5. **Therapeutic target (BACE1/FGF19 axis)** – Prioritized because multiple risk genes converge on shared pathways; dataset supplies HR; external evidence mixed (BACE1 inhibitors mainly in AD); next step: high-throughput screening in patient-derived organoids; current conclusion: exploratory hypothesis.

**Evidence grounding**  
All statistical claims derive from the supplied cohort (direct evidence: HR, P, FDR). Pathway assignments use batch GO/KEGG/Reactome annotations (pathway/ontology evidence). Disease associations draw from literature (e.g., INHBB, CDX2) and STRING (protein/regulatory evidence). No independent-cohort statistics are supplied; all external records are contextual only. Sources within the same category (e.g., multiple PubMed hits for INHBB) are not independent.

**Limitations and alternative explanations**  
- Association-versus-causation ambiguity: HR reflects correlation, not mechanistic causality.  
- Probe-ID nonspecificity: many entries are microarray probes rather than fully annotated genes.  
- Absence of independent-cohort replication statistics.  
- Potential tumor-purity or stromal-composition bias, especially for mitochondrial genes.  
- Treatment-exposure heterogeneity not specified; batch/platform effects possible in microarray data.  
- Small-subgroup effects if stage or microsatellite-instability stratification was not performed.  

These possibilities could be investigated by laser-capture microdissection, single-cell RNA-seq, or matched normal-tissue controls.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=30, external claims checked=0, external mismatches=0, status=passed.

Answer model API: xAI / grok-4.6

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
